Trial Profile
A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 14 Feb 2020 Planned End Date changed from 31 Dec 2019 to 31 Oct 2020.
- 14 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Oct 2020.